SubHero Banner

Kymriah (tisagenlecleucel) – New indication

May 1, 2018 - Novartis announced the FDA approval of Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Download PDF